June 16, 2008
The Endocrine Society’s 90th Annual Meeting
Adolescent women with obesity and polycystic ovary syndrome treated with oral contraceptives showed a reduction in weight with a lifestyle modification program, according to the results from a recent study.
Kathleen M. Hoeger, MD, associate professor, department of obstetrics and gynecology, Rochester, NY, presented the results of this randomized, placebo controlled trial today at The Endocrine Society’s 90th Annual Meeting, held in San Francisco.
The researchers examined the role of metformin on the metabolic impact of oral contraceptives in obese adolescents who were enrolled in a lifestyle modification program. They assigned 36 participants to an oral contraceptive (30 mcg ethinyl estradiol, 3.0 mg drosperinone) and either 2,000 mg/day of metformin or placebo, according to the study.
Metabolic syndrome was present in 30% of participants, and impaired glucose tolerance was present in 25% of participants; 70% of participants met lifestyle goals for weight loss and exercise.
Metabolic syndrome was present in 14% of the participants in the metformin group and in 15% of the placebo group, according to the study. Ferriman-Galway scores decreased by 32.3% in the metformin group (P=.002) and by 31% in the placebo group (P<.001). - by Christen Haigh For more information: * Hoeger KM, Kochman L, Cherry T, et al. OR28-6. A randomized, placebo controlled trial of metformin in combination with lifestyle modification in obese adolescent women with polycystic ovary syndrome (PCOS) treated with oral contraceptives. Presented at: The Endocrine Society’s 90th Annual Meeting; June 15-18; San Francisco.